Evaluation of BRCA1/2 mutation status among women with triple-negative breast cancer. This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This abstract does not include a full text ...
GOLDEN, Colo., Nov. 28, 2022 /PRNewswire/ -- Theralink Technologies (THER) (OTC: THER) ("Theralink" or the "Company"), a precision oncology company with a novel phosphoprotein-based assay for breast ...
Focused Protein Profiling Strategies and Reverse-phase Arrays Drive Growth Multiplexed protein measurements using protein microarrays have several promising applications in drug discovery and clinical ...
Predicting cancer dependencies from molecular data can help stratify patients and identify novel therapeutic targets. Recently available data on large-scale cancer cell line dependency allow a ...
Golden, Colorado & Nashville, Tennessee, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies (OTC: THER), a precision oncology company with an exclusively licensed commercial RPPA (reverse phase ...
RICHMOND, VIRGINIA, UNITED STATES, August 3, 2023/EINPresswire.com/ -- The Virginia Innovation Partnership Corporation (VIPC) today announced that George Mason ...
Emanuel Petricoin, Co-Director, Center for Applied Proteomics and Molecular Medicine (CAPMM), received funding from Georgiamune, Inc., for a project in which Georgiamune, Inc., will provide cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results